MRI、分子乳腺成像与对比增强乳腺X线摄影在新诊断乳腺癌中的诊断效能
该前瞻性研究纳入102例活检证实的乳腺癌患者,比较MRI、对比增强乳腺X线摄影(CEM)和分子乳腺成像(MBI)对病变范围的评估与病理结果。三种方法对110个原发恶性肿瘤的检出率相似(MRI 93%、CEM 91%、MBI 92%),但MRI发现更多非原发可疑良性病变,导致额外活检阳性预测值降低(MRI 28%、CEM 52%、MBI 44%)。所有方法均高估原发肿瘤大小,尤其MRI。
要点
- MRI发现更多非原发可疑病变,额外活检阳性预测值仅28%,低于CEM的52%和MBI的44%。
- 三种方法均高估原发肿瘤大小,MRI高估超过1.5 cm的比例最高(24%)。
核心结论
- CEM、MBI和MRI对乳腺癌原发灶检出率相似;MRI发现更多非原发可疑良性病变,导致额外活检阳性预测值降低;三种方法均高估原发肿瘤大小,尤其MRI。
研究设计与样本
- HIPAA合规的前瞻性研究,2014年10月至2018年4月纳入102例活检证实的乳腺癌女性,99例完成方案;8名放射科医生独立前瞻性解读MRI、CEM和MBI,并盲于其他方法结果;以病理为参考标准。
诊断标准与关键数值
- 110个原发恶性肿瘤中,MRI检出102个(93%;95%CI:86%,97%),CEM检出100个(91%;95%CI:84%,96%),MBI检出101个(92%;95%CI:85%,96%)。
- 未接受新辅助化疗患者中,MRI高估24%(17/72)的原发恶性肿瘤超过1.5 cm,CEM为11%(8/70),MBI为15%(11/72)。
- 额外活检阳性预测值:MRI 13/46(28%;95%CI:17%,44%),CEM 14/27(52%;95%CI:32%,71%),MBI 11/25(44%;95%CI:24%,65%);总体P=.01。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Staging newly diagnosed breast cancer by using dynamic contrast material-enhanced MRI is limited by access, high cost, and false-positive findings. The utility of contrast-enhanced mammography (CEM) and 99mTc sestamibi-based molecular breast imaging (MBI) in this setting is largely unknown. Purpose To compare extent-of-disease assessments by using MRI, CEM, and MBI versus pathology in women with breast cancer. Materials and Methods In this HIPAA-compliant prospective study, women with biopsy-proven breast cancer underwent MRI, CEM, and MBI between October 2014 and April 2018. Eight radiologists independently interpreted each examination result prospectively and were blinded to interpretations of findings with the other modalities. Visibility of index malignancies, lesion size, and additional suspicious lesions (malignant or benign) were compared during pathology review. Accuracy of index lesion sizing and detection of additional lesions in women without neoadjuvant chemotherapy were compared. Results A total of 102 women were enrolled and 99 completed the study protocol (mean age, 51 years ± 11 [standard deviation]; range, 32-77 years). Lumpectomy or mastectomy was performed in 71 women (79 index malignancies) without neoadjuvant chemotherapy and in 28 women (31 index malignancies) with neoadjuvant chemotherapy. Of the 110 index malignancies, MRI, CEM, and MBI depicted 102 (93%; 95% confidence interval [CI]: 86%, 97%), 100 (91%; 95% CI: 84%, 96%), and 101 (92%; 95% CI: 85%, 96%) malignancies, respectively. In patients without neoadjuvant chemotherapy, pathologic size of index malignancies was overestimated with all modalities (P = .02). MRI led to overestimation of 24% (17 of 72) of malignancies by more than 1.5 cm compared with 11% (eight of 70) with CEM and 15% (11 of 72) with MBI. MRI depicted more (P = .007) nonindex lesions, with sensitivity similar to that of CEM or MBI, resulting in lower positive predictive value of additional biopsies (13 of 46 [28%; 95% CI: 17%, 44%] for MRI; 14 of 27 [52%; 95% CI: 32%, 71%] for CEM; and 11 of 25 [44%; 95% CI: 24%, 65%] for MBI (overall P = .01). Conclusion Contrast-enhanced mammography, molecular breast imaging, and MRI showed similar detection of all malignancies. MRI depicted more nonindex suspicious benign lesions than did contrast-enhanced mammography or molecular breast imaging, leading to lower positive predictive value of additional biopsies. All three modalities led to overestimation of index tumor size, particularly MRI. © RSNA, 2019 Online supplemental material is available for this article.
引用
- Sumkin JH, Berg WA, Carter GJ, et al. Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer. Radiology. 2019. PMID: 31660801. doi:10.1148/radiol.2019190887
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。